2018 MARKET SHARE TRENDS**
Antihemophilic Factor Figure 72: Commercial
Figure 73: Medicare
BeneFix Factor VIII (recombinant) NovoSeven Xyntha
Humate-P
Koate
Figure 74: Medicaid
BeneFix Factor VIII (recombinant) NovoSeven Xyntha
Humate-P
Koate
Alphanate Humate-P
Market Share
Market Share
Market Share
2017
2017
2017
12%
57%
5%
20% 3%
63% 3%
2018
28%
45%
14%
Annual Cost per Patient 2017
2018
$465,970 $251,008 $40,083 $347,198 $884,828 $313,030
$217,675 $170,749 $48,545 $166,181 $101,309 $199,619
Allowed Amount PMPM
4% 2018
28%
9%
Brand BeneFix Factor VIII (recombinant) Humate-P Koate NovoSeven Xyntha
17%
30%
$0.12
$0.10
$0.02
$89,062 $408,630 $2,934 $511,355 $22,972 $652,981
$6,800 $23,656 $11,329 $532,739 $69,568 $959,837
$0.05
38%
Brand Alphanate BeneFix Factor VIII (recombinant) Humate-P NovoSeven
Allowed Amount PMPM
$0.05 $0.01
10%
2017
2018
-$75,079 $35,785 $11,581 $2,300
$367,799 $12,970 $24,690 $2,543 $29,937
$0.03 $0.01 $0.01
$0.01 $0.01
$0.07
2018 Total: $0.48
14%
Annual Cost per Patient 2018
$0.68
$0.48
2017 Total: $1.15
33% 1%
29%
2017
Allowed Amount PMPM
$0.22
$0.05
13%
43%
3%
$0.07 $0.18
19%
2018
Annual Cost per Patient
Brand BeneFix Factor VIII (recombinant) Humate-P Koate NovoSeven Xyntha
27%
4%
5% 4%4%
6%
BeneFix Factor VIII (recombinant) NovoSeven
$0.78
2017 Total: $1.92
2018 Total: $3.31
$0.11
2017 Total: $0.10
$0.04
2018 Total: $0.73
$0.02 $0.61
$0.22 $0.02
$0.52
$2.45
$0.05
$0.68
$0.02
**Only drugs with $0.01 PMPM or greater were included in market share analysis.
2019 / MAGELLANRX.COM/TRENDREPORT
40
9%